Phase I Study of the Combination of Apatinib and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin)
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Rivoceranib (Primary) ; Fluorouracil; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions
- 26 Jan 2018 Planned number of patients changed from 9 to 18.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.
- 13 Dec 2017 Planned End Date changed from 14 Aug 2019 to 30 Jun 2019.